


# PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

## Complete baseline ADHD assessment & offer medication to adults if:

- Their ADHD symptoms are still causing significant impairment in at least one domain after environmental modifications have been implemented and reviewed

For pre-treatment assessment & treatment planning see [NICE Guidance](#) & print/provide patient information leaflets from [Choice and medication](#) website



## PRESCRIBING ADVICE FOR ALL PATIENTS

Review diagnosis and co-morbidities if expected response to treatment is not observed, especially when changing type of drug treatment (stimulant to non-stimulant, and vice versa). Seek second opinion or refer to tertiary services any adult unresponsive to one or more stimulants or one non-stimulant

Consider shared care (where this has been agreed) once patient is clinically stable.

Consider adjunctive therapies only with advice from tertiary service: e.g. atypical antipsychotics (co-existing pervasive aggression, rages or irritability) or guanfacine (both unlicensed)<sup>1</sup>

1. For advice on appropriate dosages or conversion, please contact a member of the Trust pharmacy team
2. Capsules may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of apple sauce or yoghurt and given immediately, and not stored for future use

Title	Prescribing Guidelines for ADHD in Adults		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 <sup>th</sup> May 2021
Protocol Number	PHARM-0091-v2	Date of Review	1 <sup>st</sup> June 2024

**PRESCRIBING GUIDELINES FOR  
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS**

[AVAILABLE METHYLPHENIDATE MODIFIED-RELEASE PREPARATIONS](#) (see guidance [here](#) for more information on relative pharmacokinetics)

Brand	Available strengths	Description	Release profile	NHS indicative price (30)	Brand	Available strengths	Description	Release profile	NHS indicative price (30)
<b>Preparations with 22% immediate-release component and 78% extended-release components</b>					<b>Preparations with 30% immediate-release component and 70% extended-release component</b>				
<b>Delmosart tablets</b>	18 mg	Yellow capsule shape tablet	Immediate-release component gives a maximum plasma concentration after 1-2 hours; extended-release component gives a second peak after 6-8 hours. Duration of action up to 12 hours.	£15.57	<b>Equasym XL capsules<sup>2</sup></b>	10 mg	Dark green opaque capsule	Immediate-release component gives a maximum plasma concentration after 1.5 hours; extended-release component gives a second peak after 6 hours. Duration of action up to 8 hours.	£25.00
	27 mg	Grey capsule shape tablet		£18.39		20 mg	Blue opaque capsule		£30.00
	36 mg	White capsule shape tablet		£21.23		30 mg	Reddish brown opaque capsule		£35.00
	54 mg	Red capsule shape tablet		£36.79	<b>Preparations with 50% immediate-release component and 50% extended-release component</b>				
<b>Xenidate XL tablets</b>	18 mg	Yellow round tablet		£15.57	<b>Medikinet XL capsules<sup>2</sup></b> <i>Take with or after breakfast</i>	5 mg	White capsule	Immediate-release component gives a rapid peak plasma concentration; extended-release component gives a second peak after 3-4 hours. Duration of action up to 8 hours.	£24.04
	27 mg	Yellow oblong tablet		£18.39		10 mg	Lilac/ white capsule		£24.04
	36 mg	White oblong tablet		£21.21		20 mg	Lilac capsule		£28.86
	54 mg	Red oblong tablet		£36.79		30 mg	Purple/ light grey capsule		£33.66
<b>Xaggitin XL tablets</b>	18 mg	Yellow capsule shape tablet		£15.58		40 mg	Purple/ grey capsule		£57.72
	27 mg	Grey capsule shape tablet		£18.40		50 mg	Violet/dark violet capsule		£62.52
	36 mg	White capsule shape tablet		£21.22	60 mg	Dark violet capsule	£67.32		
	54 mg	Red/brown capsule shape tablet		£36.80	<b>Ritalin XL capsules<sup>2</sup></b> <i>Can be taken with or without food</i>	10 mg	Brown opaque capsule	Immediate-release component gives a rapid peak plasma concentration at 1-2 hours; extended-release component gives a second peak after 4 hours. Duration of action up to 8 hours.	£23.92
<b>Concerta XL tablets</b>	18 mg	Yellow capsule shape tablet	£31.19	20 mg		White opaque capsule	£28.72		
	27 mg	Grey capsule shape tablet	£36.81	30 mg		Yellow opaque capsule	£33.49		
	36 mg	White capsule shape tablet	£42.45	40 mg		Brown opaque capsule	£57.43		
	54 mg	Red capsule shape tablet	£73.62	60 mg		Brown and yellow opaque capsule	£66.98		
<b>Matoride XL tablets</b>	18 mg	Yellow round tablet	£15.58						
	36 mg	White round tablet	£21.22						
	54 mg	Pink round tablet	£36.80						

Title	Prescribing Guidelines for ADHD in Adults		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 <sup>th</sup> May 2021
Protocol Number	PHARM-0091-v2	Date of Review	1 <sup>st</sup> June 2024